Education
About Us
Working with TipRanks
Follow Us
Mesoblast (MESO)
NASDAQ:MESO
MESO Stock Chart & Stats
$17.65
-$0.53(-2.96%)
At close: 4:00 PM EST
$17.65
-$0.53(-2.96%)
Day’s Range― - ―
52-Week Range$9.61 - $21.50
Previous CloseN/A
Volume155.35K
Average Volume (3M)224.36K
Market Cap
$2.31B
Enterprise Value$1.35B
Total Cash (Recent Filing)$161.16M
Total Debt (Recent Filing)$128.16M
Price to Earnings (P/E)―
Beta1.45
Next Earnings
Feb 26, 2026EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.43
Shares Outstanding129,715,870
10 Day Avg. Volume247,243
30 Day Avg. Volume224,356
Financial Highlights & Ratios
PEG Ratio2.44
Price to Book (P/B)2.20
Price to Sales (P/S)76.48
P/FCF Ratio-25.95
Enterprise Value/Market Cap0.59
Enterprise Value/Revenue78.71
Enterprise Value/Gross Profit-37.75
Enterprise Value/Ebitda-23.27
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Market ExpansionExpansion plans for Ryoncil include targeting adult severe steroid-refractory acute graft versus host disease, potentially tripling the current market size.
Regulatory ProgressPositive feedback from the FDA on potential accelerated BLA filing for rexlemestrocel in chronic heart failure indicates promising regulatory progress.
Revenue GrowthRyoncil gross sales in steroid-refractory acute graft vs. host disease increased to $21.9M in the September quarter, up 66% from the June quarter.
Bears Say
Mesoblast News
MESO FAQ
What was Mesoblast’s price range in the past 12 months?
Mesoblast lowest stock price was $9.61 and its highest was $21.50 in the past 12 months.
What is Mesoblast’s market cap?
Mesoblast’s market cap is $2.31B.
When is Mesoblast’s upcoming earnings report date?
Mesoblast’s upcoming earnings report date is Feb 26, 2026 which is in 40 days.
How were Mesoblast’s earnings last quarter?
Mesoblast released its earnings results on Aug 28, 2025. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of -$0.373 by -$0.057.
Is Mesoblast overvalued?
According to Wall Street analysts Mesoblast’s price is currently Overvalued.
Does Mesoblast pay dividends?
Mesoblast does not currently pay dividends.
What is Mesoblast’s EPS estimate?
Mesoblast’s EPS estimate is -0.07.
How many shares outstanding does Mesoblast have?
Mesoblast has 129,715,870 shares outstanding.
What happened to Mesoblast’s price movement after its last earnings report?
Mesoblast reported an EPS of -$0.43 in its last earnings report, missing expectations of -$0.373. Following the earnings report the stock price went down -13.292%.
Which hedge fund is a major shareholder of Mesoblast?
Currently, no hedge funds are holding shares in MESO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Mesoblast Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
MESO Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 12.3K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 3.3%
Last 30 Days ▼ 3.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
3.88%
12-Months-Change
Fundamentals
Return on Equity
-18.96%
Trailing 12-Months
Asset Growth
17.27%
Trailing 12-Months
Company Description
Mesoblast
Mesoblast Limited, a biopharmaceutical company, develops and commercializes allogeneic cellular medicines in the United States, Australia, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company's products under the Phase III clinical trials include remestemcel-L for the treatment of steroid refractory acute graft versus host disease, as well as acute respiratory distress syndrome due to COVID-19 infection; Rexlemestrocel-L to treat advanced chronic heart failure; and MPC-06-ID for chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV for the treatment of biologic refractory rheumatoid arthritis diabetic nephropathy. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. for the treatment of wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.
MESO Company Deck
MESO Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call illustrated significant growth and successful product launch achievements, particularly with Ryoncil's market penetration and FDA approval. However, increased operational expenses and revaluation-related losses presented financial challenges. Overall, the company's positive strides in market access and regulatory feedback indicate strong potential for future growth.View all MESO earnings summariesTechnical Analysis
Sarepta Therapeutics
―
Cogent Biosciences
―
Adaptive Biotechnologies
―
Harmony Biosciences Holdings
―
Immunocore Holdings
―
Ownership Overview
―
Insiders
0.01% Mutual Funds
0.07% Other Institutional Investors
99.44% Public Companies and
Individual Investors